Xueba’s medical black technology system

Chapter 238 Another giant falls to Alzheimer’s disease
Hengrui Medicine.

The first thing Sun Piao does every morning is to turn on his computer and browse today's international news.

As the chairman of a domestic pharmaceutical giant, Sun Piao naturally pays attention to social affairs and the trends of other international pharmaceutical giants.

However, when Sun Piao opened the news this morning, a piece of news immediately caught Sun Piao's attention.

"Pharmaceutical giant Eli Lilly has persisted in developing the Alzheimer's disease drug Solanezumab, which targets "β-amyloid" for more than ten years, and has completely failed."

"Solanezumab failed to clear or prevent beta-amyloid plaque buildup or slow cognitive decline in patients with early-stage Alzheimer's disease,"

The clinical trial failed to meet its primary endpoint.Eli Lilly immediately announced that it would stop the development of Solanezumab, which also declared the failure of this ten-year-long research and development of new drugs for Alzheimer's disease. "

When seeing this news, Sun Piao couldn't help but shook his head. Another pharmaceutical giant stumbled into the huge pit of Alzheimer's disease.

This is not the first time Sun Piao has seen similar news.

Over the years, research on Alzheimer's disease has emerged one after another, and various theories have made breakthroughs. It seems that conquering Alzheimer's disease is close at hand.

But only Sun Piao and others know.

For pharmaceutical giants like them, Alzheimer's disease is like a curse that cannot be broken. This is a recognized pitfall.

Of course, there are also pharmaceutical companies that do not believe in evil, such as pharmaceutical giants such as Pfizer, Roche, and Johnson & Johnson.

These pharmaceutical giants believe that they need technology and capital, and as long as they are given enough time, they will definitely be able to develop drugs.

Moreover, there are so many Alzheimer's patients in the world. Once the drug is developed, the market potential is absolutely huge and it will definitely bring them exponential benefits.

Based on this idea, major pharmaceutical giants have invested huge sums of money to start their own research on Alzheimer's disease.

But in the end, it failed unexpectedly, and those huge financial investments ended up sinking into nothing.

The major pharmaceutical giants were severely beaten by Alzheimer's disease, until their heads were bleeding.

Pfizer even directly announced that the company would give up the development of Alzheimer's drugs in the future.

They cited high R&D costs and poor drug efficacy as the reasons.

This made Sun Piao couldn't help but feel scared. He had thought about trying to develop drugs for Alzheimer's disease before, but it was thanks to Zhao Rui that he stopped him in time.

Otherwise, Sun Piao estimates that Hengrui Company would be in a worse situation than those pharmaceutical companies now.

However, this also made Sun Piao worried.

Pharmaceutical giants such as Pfizer, Roche, and Merck have failed one after another. If this trend continues, they will fail two or three more times.

I'm afraid no pharmaceutical company is really willing to study Alzheimer's drugs anymore, right?
Thinking of this, Sun Piao couldn't help but sigh.

However, this was not what Sun Piao had to consider. After browsing, Sun Piao closed the news interface.

In the study room.

Lu Liang looked at the reports on the news about the failure of Eli Lilly's drug development.

This report caused quite a stir, but the movement was mainly concentrated in the pharmaceutical industry.

"I think the problem still lies in the β-amyloid hypothesis. There is definitely something wrong with this hypothesis. I don't know who proposed it back then."

“But the β-amyloid hypothesis was put forward based on strong histopathological, genetic, and biochemical evidence, and facts have also proven that such amyloid deposition plaques do exist outside the nerve cells of those patients! "How is this thing more difficult to solve than cancer?"

"After all, it involves the nervous system. Some of the things that involve the nervous system are simple."
Every once in a while, though, news comes out that Alzheimer’s drug development has failed.

But now that pharmaceutical giants like Eli Lilly have failed, this undoubtedly makes the medical community feel more desperate about Alzheimer's disease.

Lu Liang turned off the news, and then turned his attention to the word document on his desktop again.

Lu Liang has almost finished writing his review. In this review, Lu Liang took a clever trick. Instead of summarizing the current research progress on Alzheimer's disease in a lengthy article, he turned to a smaller topic - —Beta amyloid.

The reason is also very simple. There are too many reviews on Alzheimer's disease. Even if he writes it, he will definitely not be able to submit it to a good journal. At most, it will be submitted to a general issue.

Therefore, Lu Liang changed his mind and wrote a review on amyloid-β, summarizing the current research progress on amyloid-β.

This review is now down to the last discussion.

Lu Liang's fingers were tapping quickly on the keyboard.

“Beta-amyloid protein has a variety of biological functions. In blood vessels, beta-amyloid protein mainly plays the role of promoting angiogenesis and repairing the blood-brain barrier.

After knocking out APP or BACE-1, the synthesis of β-amyloid protein is inhibited. It can be seen that the hindbrain and retinal blood vessels are shorter and the cerebral blood vessel branches are fewer, which increases the mortality after ischemic injury. "

"Also the function of beta-amyloid is affected by its location and concentration.

Changes in β-amyloid within cells, expression in different cells or different locations in the body, too much or too little can lead to functional defects. "

To put it simply, too much beta-amyloid protein can lead to abnormal deposition and cause Alzheimer's disease.

But if there is less beta-amyloid, it will also have some adverse effects.

Lu Liang's mind was spinning rapidly, summarizing some of the current research progress on β-amyloid protein.

After typing the last word, Lu Liang breathed a sigh of relief.

This review of the progress of Alzheimer's disease research is finally completed.

"The system will give you a score."

After completing the review, Lu Liang couldn't wait to let the system come out with the score.

Soon, Lu Liang saw the system panel appear in front of him, and the corresponding source point was given.

[Source point +0.3. 】

There are only 0.3 source points?

This means that this review can only be published in a zone three or core journal.

Lu Liang looked a little regretful. He thought that the level of his review could reach 0.4 source points and be published in a District [-] Sci.

It seems that there is no way to cheat the system.

However, Lu Liang was satisfied to be able to submit his article to a core journal. No matter how much he said it, it was better than submitting his article to those general journals.

Lu Liang checked his review and after confirming that there were no problems, he submitted the review.

(End of this chapter)